Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Liminatus Pharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
2.69
General and administrative
0.64
2.97
Operating expenses
3.33
2.97
Operating income
-3.33
-2.97
Interest expense
0.34
0.22
Interest income
0.12
0.08
Other non-operating income
-0.22
-7.24
Net income
-3.55
-10.2
EBITDA
-2.97
EPS, basic
-0.20
-0.43
EPS, diluted
-0.20
-0.43
Shares, basic (weighted)
17.5
23.8
Shares, diluted (weighted)
17.5
23.8
Balance sheet
FY2025
FY2025
Cash and equivalents
0
0.34
Other current assets
0.16
0.16
Total current assets
5.28
0.5
Property, plant and equipment
0
0.01
Total assets
5.41
0.51
Accounts payable
1.48
0.58
Accrued liabilities
0
Short-term debt
20
1.44
Total current liabilities
24.7
10.3
Total liabilities
24.7
10.3
Paid-in capital
9.32
29.1
Retained earnings
-28.7
-38.9
Shareholders' equity
-19.3
-9.81
Total equity
-19.3
-9.81
Total liabilities and equity
5.41
0.51
Shares outstanding
17.5
27.1
Cash flow statement
FY2025
FY2025
Net income
-3.55
-10.2
Depreciation and amortization
0
Change in payables
-0.01
-4.04
Cash from operations
-1.45
-9.96
Capital expenditures
-0.01
Cash from investing
-2.85
-0.79
Cash from financing
3.92
11
Net change in cash
-0.38
0.28
Free cash flow
-9.98
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.20 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-4,166.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-367.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-90.5%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
35.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.12x
Current assets / current liabilities.
Quick ratio
0.99x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.99x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.08
Cash from operations / diluted weighted shares.
Book value per share
$0.01
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
937x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
937x
Market cap / tangible book value, when positive.
Earnings yield
-4.4%
Net income / market cap (the inverse of P/E).
Was Liminatus Pharma, Inc. profitable in fiscal 2025?
No. It reported a net loss of $10.2M.
How much free cash flow did Liminatus Pharma, Inc. generate in fiscal 2025?
Cash from operations of $10.0M minus capital expenditures of $13.1K left free cash flow of -$10.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.